CA2424317A1 - Mammalian two-hybrid system for screening for modulators of the accumulation of metabolic products - Google Patents

Mammalian two-hybrid system for screening for modulators of the accumulation of metabolic products Download PDF

Info

Publication number
CA2424317A1
CA2424317A1 CA002424317A CA2424317A CA2424317A1 CA 2424317 A1 CA2424317 A1 CA 2424317A1 CA 002424317 A CA002424317 A CA 002424317A CA 2424317 A CA2424317 A CA 2424317A CA 2424317 A1 CA2424317 A1 CA 2424317A1
Authority
CA
Canada
Prior art keywords
nucleic acid
cell
chimeric protein
metabolic product
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002424317A
Other languages
English (en)
French (fr)
Inventor
Osamu Tetsu
Kenichi Wakita
Frank Mccormick
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California, San Diego
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2424317A1 publication Critical patent/CA2424317A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1055—Protein x Protein interaction, e.g. two hybrid selection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Plant Pathology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Materials By Optical Means (AREA)
CA002424317A 2000-10-13 2001-10-09 Mammalian two-hybrid system for screening for modulators of the accumulation of metabolic products Abandoned CA2424317A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/687,593 US6787321B1 (en) 2000-10-13 2000-10-13 Mammalian two-hybrid system for screening for modulators of the accumulation of metabolic products
US09/687,593 2000-10-13
PCT/US2001/031745 WO2002031201A2 (en) 2000-10-13 2001-10-09 Mammalian two-hybrid system for screening for modulators of the accumulation of metabolic products

Publications (1)

Publication Number Publication Date
CA2424317A1 true CA2424317A1 (en) 2002-04-18

Family

ID=24761035

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002424317A Abandoned CA2424317A1 (en) 2000-10-13 2001-10-09 Mammalian two-hybrid system for screening for modulators of the accumulation of metabolic products

Country Status (7)

Country Link
US (2) US6787321B1 (enExample)
EP (1) EP1327003B1 (enExample)
JP (1) JP2004511237A (enExample)
AT (1) ATE520788T1 (enExample)
AU (1) AU2001296805A1 (enExample)
CA (1) CA2424317A1 (enExample)
WO (1) WO2002031201A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1573058T3 (da) * 2002-12-18 2012-01-16 Chromagenics Bv Fremgangsmåde til forbedring af proteinproduktion
BRPI0610821A2 (pt) * 2005-05-19 2010-07-27 Wyeth Corp método de identificação de compostos que modulam a interação de receptor de androgênio com beta-catenina
US20100099096A1 (en) * 2007-02-28 2010-04-22 The Brigham And Women's Hospital, Inc. Compositions and Methods for Identifying Factors Affecting Protein Stability
US20100197767A1 (en) * 2007-07-11 2010-08-05 Lior Nissim Nucleic acid construct systems capable of daignosing or treating a cell state
US20120156180A1 (en) * 2009-08-10 2012-06-21 The Board Of Trustees Of The University Of Illinois Compositions and methods for the treatment of krabbe and other neurodegenerative diseases
GB2584211B (en) * 2017-11-16 2023-05-24 Synthex Inc Selective modulation of protein-protein interactions
JP7773376B2 (ja) 2019-05-15 2025-11-19 シンセックス， インコーポレイテッド タンパク質の選択的分解

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0370813A3 (en) 1988-11-25 1991-06-19 Exemplar Corporation Rapid screening mutagenesis and teratogenesis assay
US5283173A (en) 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
US5525490A (en) 1994-03-29 1996-06-11 Onyx Pharmaceuticals, Inc. Reverse two-hybrid method
EP0830459B1 (en) 1995-04-11 2007-01-24 The General Hospital Corporation Reverse two-hybrid systems
FR2734567B1 (fr) 1995-05-26 1997-08-08 Commissariat Energie Atomique Proteines chimeriques activant la transcription par la polymerase iii, leur utilisation pour la detection et l'analyse des interactions entre proteines, et genes codant pour lesdites proteines
USH1892H (en) 1995-07-27 2000-10-03 Pharmacia And Upjohn Company High volume nutrient based yeast two-hybrid assay for the identification of specific protein:protein interacting inhibitors
US5948620A (en) 1996-08-05 1999-09-07 Amersham International Plc Reverse two-hybrid system employing post-translation signal modulation
US6133027A (en) 1996-08-07 2000-10-17 City Of Hope Inducible expression system
ATE289353T1 (de) 1996-12-11 2005-03-15 Bristol Myers Squibb Co Prokaryotisches zwei-hybrid system
US5851775A (en) * 1997-03-20 1998-12-22 Johns Hopkins University β-catenin, Tcf-4, and APC interact to prevent cancer
US5885779A (en) * 1997-09-09 1999-03-23 University Of British Columbia Repressed trans-activator system for characterization of protein-protein interactions
US6242253B1 (en) * 1997-10-09 2001-06-05 Regents Of The University Of California IkB kinase, subunits thereof, and methods of using same

Also Published As

Publication number Publication date
ATE520788T1 (de) 2011-09-15
WO2002031201A2 (en) 2002-04-18
EP1327003B1 (en) 2011-08-17
EP1327003A2 (en) 2003-07-16
US6787321B1 (en) 2004-09-07
US7358086B2 (en) 2008-04-15
AU2001296805A1 (en) 2002-04-22
JP2004511237A (ja) 2004-04-15
US20040265791A1 (en) 2004-12-30
WO2002031201A3 (en) 2002-11-21

Similar Documents

Publication Publication Date Title
Acsadi et al. Dystrophin expression in muscles of mdx mice after adenovirus-mediated in vivo gene transfer
US20050037390A1 (en) Methods and compositions for modulating erythropoietin expression
Wybranietz et al. Enhanced suicide gene effect by adenoviral transduction of a VP22-cytosine deaminase (CD) fusion gene
Zhadina et al. Ubiquitin-dependent virus particle budding without viral protein ubiquitination
Kohler et al. Functional definition of the mutation cluster region of adenomatous polyposis coli in colorectal tumours
US20100099108A1 (en) Method for Detecting, Isolating, and Characterizing Cells from Body Samples by Transfection with Nucleic Acid Constructs
Kumagai et al. Eradication of Myc-overexpressing small cell lung cancer cells transfected with herpes simplex virus thymidine kinase gene containing Myc-Max response elements
Bergelson et al. Cooperative interaction between Ets and AP-1 transcription factors regulates induction of glutathione S-transferase Ya gene expression
EP1327003B1 (en) Mammalian two-hybrid system for screening for modulators of the accumulation of metabolic products
WO2001075168A1 (en) Control of a gene induced by oxidized lipids in human artery wall cells
WO2009151172A1 (en) Lentiviral vectors comprising ferritin gene and use thereof
Yang et al. Development of endothelial-specific single inducible lentiviral vectors for genetic engineering of endothelial progenitor cells
US7741113B2 (en) Cell-specific molecule and method for importing DNA into osteoblast nuclei
EP0842426B1 (en) Improvements in or relating to methods of screening substances
Strauss et al. A novel gene transfer strategy that combines promoter and transgene activities for improved tumor cell inhibition
WO2004043371A2 (en) Methods and compositions for modulating p53 transcription factor
EP1147208A2 (en) Compositions and methods for intraductal gene therapy
AU2003245342A1 (en) Control sequences of the human corin gene
JPH11509316A (ja) 結合アッセイにおけるまたはそれに関する改良
US6982148B2 (en) Progressive elevated gene-3 (PEG-3) induces aggressive cancer phenotype and regulates angiogenesis
US20020111289A1 (en) CDK4 is a target of c-MYC
AU2001249761B2 (en) Control of a gene induced by oxidized lipids in human artery wall cells
Ghattas Footprinting in vivo of the Rous sarcoma virus transcription control region
Morrison Targeting gene therapy to intraperitoneal ovarian carcinoma
Liu The regulation of beta-catenin turnover

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20140722